(Q24653374)

Continuous cultures of fused cells secreting antibody of predefined specificity

published in

Monoclonal Antibodies

0 references

volume

1

0 references

issue

2

0 references

page(s)

104-11

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

Immunogenicity of protein therapeutics

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

Primary immune response to sheep red blood cells (SRBC) as the conventional T-cell dependent antibody response (TDAR) test

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

Managing premedications and the risk for reactions to infusional monoclonal antibody therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

Monoclonal antibody first dose cytokine release syndromes-mechanisms and prediction

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

The calm after the cytokine storm: lessons from the TGN1412 trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

Fungal infections complicating tumor necrosis factor alpha blockade therapy.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

Drug-induced lupus due to anti-tumor necrosis factor alpha agents

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

Alemtuzumab in chronic lymphocytic leukemia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

Infection and musculoskeletal conditions: Bacterial and opportunistic infections during anti-TNF therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

Natalizumab and progressive multifocal leucoencephalopathy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

Methods of evaluating immunotoxicity

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

Fully human therapeutic monoclonal antibodies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

Tolerability and safety of rituximab (MabThera).

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

Preclinical safety testing of biotechnology-derived pharmaceuticals: understanding the issues and addressing the challenges

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

Immunosuppressive drugs and cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

Nonclinical safety evaluation of biotechnologically derived pharmaceuticals

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725414

Severe anaphylactic reaction during the second infusion of infliximab in a patient with psoriatic arthritis

28 September 2017

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.2.7909

Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.2.7909

Potential anaphylactic shock with abciximab readministration

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.2.7909

Preclinical safety evaluation of biotechnology-derived pharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.2.7909

Preclinical safety testing of monoclonal antibodies: the significance of species relevance.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.2.7909

Immunotoxicity evaluation by immune function tests: focus on the T-dependent antibody response (TDAR) [Overview of a Workshop Session at the 45th Annual Meeting of the Society of Toxicology (SOT) March 5-9, 2006 San Diego, CA].

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.2.7909

T-dependent antigen response (TDAR) tests: meta-analysis of results generated across multiple laboratories.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.2.7909

Adverse consequences of immunostimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.2.7909

Infections Associated with Tumor Necrosis Factor-α Antagonists

21 January 2018

1 reference

12 December 2020

Clinical immunotoxicity of therapeutic proteins

1 reference

12 December 2020

Complement activation plays a key role in the side-effects of rituximab treatment

1 reference

12 December 2020

Assessment of Immunobiological Effects Induced by Chemicals, Drugs or Food additives. I. Tier Testing and Screening Approach

1 reference

12 December 2020

Factors that contribute to the immmunogenicity of therapeutic recombinant human proteins

1 reference

12 December 2020

Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab

1 reference

12 December 2020

Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study

1 reference

12 December 2020

Monoclonal antibody pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

Role of natural killer cells in immunotoxicity: an update

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.2.7909

7 January 2021